Xylem (XYL): Gangbangcheon B × Geochajesi 8/20 — Global Pure-Play Water #1, PFAS & AI Water Demand Structural Tailwinds, Thin Safety Margin at Current Price
Global #1 integrating the full water cycle (transport–treatment–measurement–service–digital) — Gangbangcheon Steps 1–4 pass at Grade A (switching-cost + technology moat, Evoqua integration ahead of plan, margin 8.9%→13.8%). Step 5 K-PER conservative upside -1% — thin safety margin + full chart bearish alignment → Gangbangcheon B × Geochajesi 8/20. Entry: sub-$100 decline (conservative K-PER 10%+ restored) or 50-day MA ($116) volume recapture.
Core Position
Global pure-play leader integrating the full water cycle (transport–treatment–measurement–service–digital) — structural tailwinds from PFAS regulation, aging infrastructure, and AI water demand protected by switching-cost and technology moats, but at current price ($109) the K-PER conservative upside is ~0%, leaving thin safety margin
Investment Thesis
Xylem (XYL) is rated "watch-and-wait — add to watchlist" at Gangbangcheon B × Geochajesi 8/20. Steps 1–4 pass at Grade A quality: structural essential-goods demand in water/wastewater infrastructure (Step 1); global pure-play #1 with pricing power and 150-country diversification (Step 2); Evoqua integration completed ahead of schedule, recurring revenue transition, $4.6B backlog (Step 3); FCF margin 10–12%, operating margin expanding 8.9%→13.8%, record revenue (Step 4). However, Step 5 K-PER conservative upside is ~-1%, falling short of the 10% threshold — thin safety margin. Chart is in full bearish alignment (200>50>20>price) with trend reversal unconfirmed, Geochajesi 8/20 — no immediate entry. Buy after price drops below $100 or after recapturing the 50-day MA ($115–116) with volume confirmation.
① Non-Financial — Switching-Cost & Tech Moat + End-to-End Integrated Position vs. ROE 9% Average + New Management Team
The core strength is a dual moat. Switching costs: water utility infrastructure has multi-decade replacement cycles and is mission-critical — customers don't switch verified suppliers easily. Technology/IP: industry-standard IP in UV/ozone disinfection, membrane/activated carbon, PFAS removal (MitiGATOR), and AMI smart metering. Position: Xylem is virtually the only end-to-end integrator across water transport–treatment–measurement–service–digital. Brand (Flygt, Sensus, YSI) and customer diversification (<5% single customer, 150 countries) also favorable. However, the 2023 all-stock Evoqua acquisition diluted ROE to 6.0% (recovering to ~9%), still below Gangbangcheon's 'outstanding compounder (ROE 15%+)' bar. Both CEO (Pine, Jan 2024) and CFO (Grogan, Oct 2023) are in their 2nd–3rd year, with long-term track records yet to accumulate. → Full 5-layer analysis, moat, and competitive landscape in the Non-Financial tab.
② Validator — Gangbangcheon B (Business Quality A) × Geochajesi 8/20 = Great Asset, Wrong Timing
Gangbangcheon 5 steps: Steps 1–4 pass strongly at Grade A quality; Step 5 K-PER conservative upside below threshold drops overall grade to B. Base K-PER (+23%) and optimistic (+56%) are attractive, but the conservative scenario (-1%) fails the 10% threshold — insufficient safety margin. Geochajesi 8/20 — Volume 2, Chart 1, Catalyst 3, Market 2. Full chart bearish alignment (200>50>20>price) is a strong negative signal, capping the Chart category at maximum 1 point. B × 8pts = timing gate not cleared, no immediate entry. → Full Gangbangcheon steps, 3 K-PER scenarios, and Geochajesi details in the Validator tab.
③ Technical — Full Bearish Alignment + Consolidating Near $105 Low, 50-day MA ($116) Recapture or Sub-$100 Further Decline as Buy Triggers
The stock fell -31% from its October 2025 high of $152 to a 52-week low of $105.29 in May 2026. Currently consolidating near ~$109, in full bearish MA alignment (200-day ~$130 > 50-day ~$115 > price $109). RSI ~40 recovering from oversold territory but pre-confirmation of a genuine bounce. Key support: $105 (52-week low/psychological floor), $100 (Gangbangcheon A upgrade price). Key resistance: $115–116 (50-day MA), $130 (200-day MA / bearish alignment exit). Buy triggers: (1) 50-day MA recapture with volume, or (2) further decline below $100 improves conservative K-PER. → Full 3 scenarios, RSI, and MA detail in the Technical tab.
Key Metrics
Price (Analysis Date)
~$109
2026-06-10 기준
Market Cap
~$26B
발행주식 237.7M
Adj. EPS (2025)
~$5.05
+19% YoY
Geochajesi
8 / 20
강방천 B · 관망
K-PER Base Target
~$134
+23% 업사이드
Order Backlog
$4.6B
약 60% 2026 인식
Bull Case
- PFAS / EU Green Deal mandatory demand — US EPA finalized PFAS drinking water standards create legally mandated demand for activated carbon, membrane systems, and MitiGATOR. The largest policy tailwind in company history. EU Green Deal tightening wastewater standards adds concurrent demand pull
- AI water demand megatrend + aging infrastructure — Company research: AI data center water demand expected to roughly double by 2050. Aging US water systems (average water main age 45 years) + IIJA infrastructure spending creates 10+ years of structural demand
- $4.6B backlog, recurring revenue transition + Evoqua ahead of schedule — ~60% of backlog recognized in 2026. Expanding service/aftermarket/SW subscription mix raises revenue visibility. Cost synergy run-rate of $130M achieved (vs. $140M target, ahead of plan). Evoqua integration execution proven
- $1.5B share buyback authorized (Feb 2026) + 15 consecutive dividend increases — Large-scale buyback near 52-week lows provides price support. 15-year streak of dividend growth establishes long-term shareholder return credibility. $350M returned in 2024
- Monopoly on end-to-end water cycle integration — No competitor provides a single-platform integration of transport–treatment–measurement–service–digital. 150-country presence with <5% single-customer concentration minimizes geographic and customer risk. Xylem Vue/Idrica digital platform accelerates subscription conversion from installed base data
Bear Case
- K-PER conservative upside ~-1% — thin safety margin + full chart bearish alignment — At current price ($109), conservative EPS growth (8%, 3yr EPS $6.36) × K-PER 17x = $108 target, -1% upside. Below 10% safety-margin threshold. Full chart bearish alignment (200-day $130 > 50-day $115 > price $109) — if $105 breaks, $100+ further downside risk
- ROE ~9% — Evoqua dilution structure + below Gangbangcheon standard — 2023 all-stock Evoqua acquisition inflated equity from $5.5B to $10.2B. ROE recovering from 6.0% (2023) to 9.0% (2025), but still 6 percentage points below Gangbangcheon's "outstanding compounder (ROE 15%+)" bar. Evoqua revenue synergies unrealized (cost synergies achieved) — a key uncertainty formally disclosed in filings
- New management team Key-man risk + organic growth stagnation — CEO (Pine) and CFO (Grogan) both in their 2nd-3rd year. Versus Decker's 10-year track record, the new team's long-run credentials remain unproven. "Purposeful walkaway" (intentional exit from low-margin revenue) + China de-risking pushes organic revenue growth to near-flat — whether margin expansion and external growth can coexist is unproven
- Tariff / FX / supply chain macro risks — Global revenue structure means USD strength creates translation headwinds (explicitly mentioned in Q1 2025 as FX headwind). Global supply chain and manufacturing exposure → tariff risk. Semiconductor component sourcing for smart metering/sensors creates supply-disruption exposure. Applied Water segment (~21% of revenue) is directly sensitive to construction/real estate cycles
- 2026 conservative guidance disappoints market + multiple analyst downgrades — Q4 2025 earnings call presented 2026 guidance somewhat below consensus expectations, triggering the stock decline. UBS downgrade and numerous target price cuts partly eroded analyst confidence. The conservative guidance disappointment was the direct catalyst for the 52-week low — risk of additional downward revisions
Technical Summary
Full bearish MA alignment in force (200-day $130 > 50-day $115 > current price $109). Stock dropped -31% from October 2025 high of $152 to May 2026 52-week low of $105.29 and is now consolidating near that low. RSI ~40 entering oversold recovery but upside trend not yet confirmed. Key support: $105 (52-week low); key resistance: $115–116 (50-day MA), $130 (200-day MA).
XYL Price Trajectory & Moving Averages (Monthly Close Est., Oct 2025–Jun 2026 + RSI Panel)
Support
S1: $105~107 (52주 저점 $105.29·심리선 컨플루언스), S2: $100 (강방천 A 상향 임계·라운드 넘버), S3: $90~95 (피보나치 지지 추정)
Resistance
R1: $115~116 (50일 이동평균선), R2: $130 (200일 이동평균선·역배열 탈출 기준), R3: $152 (2025년 10월 52주 고점)
Trend Analysis
Long-term (200-day MA ~$130, declining): bearish trend in progress. Medium-term (50-day MA ~$115, declining): price below 50-day — bearish alignment. Short-term: $105–$109 box consolidation. MA alignment: 200 > 50 > 20 > price — full bearish order. Death cross (50-day crossing below 200-day) confirmed around Feb–Mar 2026. Underperforming the market.
Momentum & Indicators
RSI ~40 — recovered from near-oversold levels (30 in February and May 2026). MACD in negative territory, histogram weakening. Broke below and now recovering toward Bollinger Band lower boundary. ~92.7% institutional ownership structurally limits persistent selling pressure.
Key Technical Points
All three moving averages in perfect bearish order. Both the 200-day and 50-day MAs remain in downtrends — recapturing the 50-day with volume is the minimum requirement for trend reversal. Unwinding the bearish alignment will take time. Entering in this configuration requires breaking through MA resistance levels in sequence to achieve profit targets.
The 52-week low of $105.29 (set May 20, 2026) is the primary support level. A break below would expose the $100 psychological floor as the next line. Paradoxically, a further decline below $100 would enter the price range that could trigger a Gangbangcheon A upgrade (improving conservative K-PER upside). Holding support could form a double-bottom pattern.
RSI has twice reached near-oversold territory (~30) in February and May 2026, and is now recovering to ~40. If price revisits the May low ($105.29) while RSI sets a higher low than February, that forms positive divergence — a short-term bounce signal. However, positive divergence alone is insufficient justification for entry in a full bearish-alignment environment.
At the current $109, the conservative K-PER upside is ~-1%, below the safety-margin threshold. A further decline below $100 would improve the upside vs. the conservative target ($108) to ~+8%, approaching the 10% threshold. $100 is both the Gangbangcheon B→A upgrade price trigger and a round-number technical support — a dual-significance zone where technical and fundamental buy rationale converge.
Trading Scenarios
Entry
1/3 now ~$109 / 1/3 on $105 support confirmation / 1/3 on 50-day ($116) volume recapture
Stop
Clean break below $100 (closing basis)
Target
Target 1 ~$134 (K-PER base, +23%) / Target 2 ~$170 (K-PER optimistic, +56%)
Assumes avg cost ~$107. 3-tranche distribution spreads bearish-alignment risk. Must not be time-sensitive capital. Long-term conviction (1–3 years) is mandatory. Stop at $100 must be set in advance.
Entry
Lump-sum entry in $95–$100 zone on further decline
Stop
Break below $88–$90
Target
Target 1 ~$134 (+37%) / Target 2 ~$170 (+72%)
Conservative K-PER upside improves to +8–15%, establishing a safety margin. Price range eligible for Gangbangcheon A upgrade. Requires patience for further decline vs. Scenario 1.
Entry
Entry on a pullback after 50-day ($115–116) volume-confirmed recapture
Stop
Re-break back below the 50-day MA
Target
Target 1 ~$134 (+16%) / Target 2 ~$170 (+47%)
Strongest entry rationale with trend reversal confirmed, but higher entry price reduces upside to Target 1. Appropriate for conservative investors who prefer to eliminate bearish-alignment risk before entering.
Bullish Signals
50-day MA ($115–116) closing break with above-average volume (key trend-reversal signal)
$105 support defended + RSI positive divergence confirmed (double-bottom setup)
2026 earnings guidance raised or consensus beat on quarterly results
PFAS regulatory enforcement acceleration news + large contract announcement
$1.5B buyback execution disclosed → reinforced downside support
Bearish Risks
Clean $105 break on closing basis → sub-$100 further decline scenario activated
Additional downward revision to 2026 earnings guidance
Formal acknowledgment that Evoqua revenue synergies cannot be realized
200-day MA continued decline + RSI re-entering oversold territory (below 30)
Geochajesi sustained decline to 6 or below
Editor Note
"Great asset, wrong timing." XYL is one of the rare large-cap industrials that passes Gangbangcheon Steps 1–4 at Grade A quality. The PFAS regulation, AI water demand, and $4.6B backlog are real. But at current price ($109), the conservative K-PER upside is -1%, and the chart is in full bearish alignment. There's no reason to rush. Add it to the watchlist and wait for one of two triggers: (1) further decline below $100 (safety margin established, Gangbangcheon A upgrade) or (2) 50-day MA recapture with volume (trend reversal confirmed). Investors with 1–3 year conviction and no forced timeline can begin a 3-tranche accumulation — but the $100 stop must be set in advance.
* Technical analysis is based on historical data and does not guarantee future returns. Final investment decisions are your own responsibility.
Xylem Growth Dashboard — Revenue Trajectory, Segment Mix, Growth Rates, Profitability Expansion (2019–2026E)
Xylem Business Model — 4-Stage Water Cycle Value Chain + 3 Revenue Structures + Structural Moat
Switching Cost & Moat
Moat Strength by Type
Switching Costs
Utility infrastructure has multi-decade replacement cycles. In mission-critical applications, switching costs (re-certification, re-integration, service disruption risk) are extremely high. Once installed, Flygt pump systems and Sensus AMI infrastructure operate for decades unless entirely replaced at the city level. The $4.6B backlog is quantitative evidence of this lock-in.
Technology / IP
Leading technology and multiple patents in UV/ozone disinfection (Wedeco), membrane/activated carbon treatment (Evoqua), PFAS removal (MitiGATOR), AMI smart metering (Sensus), and water quality analytics (YSI/WTW). High-R&D-intensity domains that are difficult to replicate. With PFAS regulations, MitiGATOR is positioned as a near-mandatory demand solution.
Brand
Flygt (global top-tier in water transport), Sensus (global AMI #1–2), YSI (water quality analytics legacy), Wedeco (leading UV disinfection) — industry-standard legacy B2B brands in each segment. Competes on premium engineering, performance, reliability, and lifecycle cost, not price. Low general consumer awareness due to B2B nature, but strong trust asset among procurement managers and engineers.
Network Effects
The Xylem Vue (Idrica) AI platform potentially exhibits data network effects: as the installed base grows, accuracy of pipe burst and leak prediction improves. AMI smart meter network expansion increases the value of water quality and consumption pattern data. However, this is still in early development — requires sufficient installed base accumulation as a prerequisite.
Cost Structure
Global economies of scale + 80/20 simplification program (eliminating low-margin product lines, reducing SKU count) is actively improving the cost structure. Operating margin progression 8.9% (2023) → 13.8% (2025) is the quantitative evidence of cost improvement. However, not yet achieving overwhelming cost advantage vs. specialist large-cap competitors like Grundfos or Veolia.
Switching costs and technology/IP are Xylem's two strongest moats. Water utility infrastructure has multi-decade replacement cycles, and in mission-critical applications, the cost of switching from a verified supplier (re-certification, re-integration, service disruption risk) is extremely high. The technology moat consists of numerous patents and know-how in UV/ozone disinfection, membrane/activated carbon treatment, PFAS removal (MitiGATOR), and AMI smart metering. Legacy B2B industry-standard brands — Flygt, Sensus, YSI, Wedeco — add trust-asset value. The Xylem Vue/Idrica digital platform is in early stages but carries the seeds of a network effect where data and analytics value rise as the installed base grows. Critically, Xylem's end-to-end position integrating water transport–treatment–measurement–service–digital within a single vendor is structurally unique — an effective competitive moat in itself.
Management & Governance
CEO: Matthew Pine (b.1971) — assumed role January 1, 2024. Joined Xylem in 2020, promoted internally through COO. Prior career: President of Carrier Residential, Vestas Wind Systems, Lennox, Trane — 25+ years in industrial/HVAC manufacturing. A planned succession from Decker's (10-year) expansion phase to Pine's "integration, simplification, margin expansion" phase. 2026 conservative guidance set some analysts off. CFO: William Grogan — joined October 2023, from IDEX Corporation CFO (solid industrial track record). Both executives are in their 2nd–3rd year, with long-term track records not yet established — a significant uncertainty. Capital allocation: Evoqua cost synergy run-rate of $130M achieved ahead of plan ($140M target), sold non-core Magneto business ($61M) — execution ability proven. $1.5B buyback authorized (Feb 2026). 15 consecutive dividend increases. Board Chair Robert Friel (ex-PerkinElmer CEO) maintains CEO/Chair separation.
Competitive Landscape
Veralto (Danaher 분사)
Spun off from Danaher in 2023 as a pure-play water quality analytics and measurement specialist. Brands including Hach, ChemTreat, and OTT HydroMet directly compete with Xylem YSI/WTW. The MCS segment has the highest overlap with Veralto.
Grundfos (사모)
World's largest pump manufacturer (~€5.5B annual revenue). Direct competitor to Flygt/Godwin in Water Infrastructure transport segment. Also investing heavily in energy efficiency and digitalization. Not publicly listed so limited financial disclosure, but market dominance makes it Xylem's largest single-segment threat.
Pentair
Residential, commercial, and industrial water treatment specialist (NASDAQ: PNR). Partial overlap with Applied Water and Water Solutions & Services segments. Since 2018 spin-off has focused on residential pool/water treatment, creating some differentiation from large utility infrastructure.
Badger Meter / Itron
Smart metering and IoT data management specialists. Direct competitors to Xylem's Sensus/AMI business within the MCS segment. Badger Meter holds a strong position in the narrow pure-play water metering niche. Itron covers multi-utility metering (electricity/gas/water) more broadly. Overlap with Xylem outside MCS is limited.
Direct competition: strong specialist competitors exist in each segment. In pumps alone, Grundfos (world's largest pump manufacturer) is the strongest rival. In water quality measurement and analytics, Danaher spinoff Veralto (water quality/measurement specialist) directly overlaps with MCS. In metering, Badger Meter and Itron compete with the MCS smart-metering business. In residential/industrial applications, Pentair competes with the Applied Water segment. In integrated water treatment services, Veolia and Suez (large environmental services groups) overlap with Water Solutions & Services. Differentiation: Xylem is essentially the only end-to-end integrator across the full water cycle — strong competitors exist in each individual segment, but no substitute is available for the integrated solution. The PFAS removal technology (MitiGATOR) and AI-based Xylem Vue platform are current differentiators, but competitors are developing similar capabilities.
ESG & Summary
Environmental: Xylem's core business is itself a frontline ESG actor — solving environmental challenges through water treatment infrastructure. PFAS removal, UV disinfection, and non-revenue water (NRW) reduction technologies directly contribute to water resource conservation and environmental protection. AI-based leak detection (Xylem Vue) has the potential to save billions of gallons of water annually. Carbon neutrality roadmap published with operational carbon reduction targets. Social: Supports water and wastewater utility infrastructure in 150 countries — directly improving safe water access for humanity. ~17,800 employees. B2B specialist with limited direct consumer impact but strong interface with public health infrastructure operators. Governance: Pure US corporation (NYSE), no VIE structure. CEO/Board Chair separation maintained. 92.7% institutional ownership creates passive-investor oversight structure. 15-year consecutive dividend growth + $1.5B buyback authorization provides high shareholder return policy transparency. Owner-risk-free professional governance commands a clear ESG premium vs. Korean conglomerates.
Key Risks
K-PER Conservative Upside ~-1% — Thin Safety Margin + Full Bearish Chart Alignment
At current price ($109), conservative EPS growth (8%, 3yr EPS $6.36) × K-PER 17x = $108 target, -1% upside. Below Gangbangcheon Step 5 safety-margin threshold (10%+), downgrading overall rating to B. Full chart bearish alignment (200>50>20>price) confirms the medium-term downtrend is not reversed. If $105 breaks, risk of further decline below $100 — which is both a psychological support and the Gangbangcheon A upgrade trigger price.
ROE ~9% — Evoqua Dilution + Revenue Synergies Unrealized
2023 all-stock Evoqua acquisition ($7.5B) inflated equity from $5.5B to $10.2B, structurally diluting ROE to 6.0%. Now recovering to ~9%, but still 6 percentage points below Gangbangcheon's "high-quality compounder (ROE 15%+)" standard. Cost synergy run-rate ($130M) has been achieved, but revenue synergy realization is explicitly noted as a key uncertainty in SEC filings. If the original Evoqua integration thesis assumed revenue synergies, current organic growth stagnation can be interpreted as an underperformance vs. expectations.
New Management Team (Pine/Grogan) Unproven Track Record + Conservative Guidance Shock
CEO Pine (assumed role Jan 2024) and CFO Grogan (joined Oct 2023) are both in their 2nd–3rd year. Unlike the decade-long track record of prior CEO Decker, the Pine leadership team has not yet demonstrated performance through a downturn or crisis. Q4 2025 earnings call presented 2026 guidance conservatively (~-8% vs. consensus), triggering a stock sell-off and UBS downgrade — denting market confidence. Guidance accuracy has become the key near-term stock price driver.
Tariff / FX / Supply Chain Macro Variables + Applied Water Cyclicality
USD strength creates translation headwinds in a global revenue structure (Q1 2025 FX headwind explicitly disclosed). Global manufacturing and supply chain exposure means direct tariff risk. Smart metering and sensor electronics component sourcing creates semiconductor supply chain sensitivity. The Applied Water segment (~21% of revenue) is directly tied to construction and real estate cycles — vulnerable to direct impact in an economic downturn. China de-risking reduces geopolitical risk but surrenders one long-term growth lever.
Gangbangcheon 4/5 passed
Gangbangcheon 5 steps: Steps 1–4 pass strongly at Grade A business quality; Step 5 K-PER conservative upside below 10% downgrades overall to Grade B. Step 1: Water/wastewater essential goods + structural growth (PFAS, infrastructure, AI water demand) ✅. Step 2: Global pure-play #1, pricing power, customer lock-in — Grade A ✅. Step 3: Evoqua integration ahead of plan, recurring revenue transition, $4.6B backlog ✅ (with new management team caveat). Step 4: FCF 10–12%, margin improvement excellent-to-average ✅ (with ROE 9% average caveat). Step 5: Conservative upside -1% → below 10% ❌ → Grade B. Geochajesi 8/20 = B × 8pts = no immediate entry.
Xylem Financial Performance — Revenue & Operating Income (bar) vs ROE & ROA (line), 2021–2025 (Reported GAAP)
Gangbangcheon 5-Step Checklist
Step 1
Industry / Infrastructure Tailwind ✅
TAM: Global water infrastructure market with structural growth (5%+ annually). Multiple tailwinds: PFAS regulatory mandatory demand (US EPA standards finalized), aging infrastructure (average US water main 45 years old), and surging AI data center water demand (internal estimate: ~2x by 2050). Essential, non-cyclical demand (utilities, drinking water, wastewater are necessity goods independent of economic cycles). Entry barriers: multiple layers of switching costs + technology/certifications + legacy brands. Organic volume near-flat but benefiting from infrastructure investment cycle (IIJA budget deployment).
Step 2
Market Position ✅ — Grade A
Global pure-play water technology leader by revenue. Pricing power: 3 consecutive years of price realization (repeatedly highlighted), shipment volumes maintained, and GPM rising → YES. "Purposeful walkaway" (intentional exit from low-margin revenue) demonstrates margin-first strategy. Customer lock-in: switching-cost type + subscription type (AMI, SW) + recurring service revenue. <5% single-customer, 150-country diversification. Pricing power, lock-in, and market position all Grade A.
Step 3
Business Model / Leadership ✅ (with New Management Team Caveat)
Scalability: Platform (Xylem Vue digital), geographic (global), vertical (services), subscription (one-time → recurring) — all four dimensions apply. Leadership: professional management (no owner risk), Evoqua integration achieved ahead of target (cost synergy $130M), non-core Magneto business sold ($61M). High revenue visibility via $4.6B backlog. 15 consecutive dividend increases. Caution: CEO (Pine, Jan 2024) and CFO (Grogan, Oct 2023) are new team — long-term track records not yet established. Evoqua revenue synergies are still in progress and unrealized.
Step 4
Financial Quality ✅ (with Average Capital Efficiency Caveat)
FCF margin: ~10–12% (est.) — satisfactory. P×Q-C: P↑ (price increases), Q→ (near-flat), C↓ (80/20 simplification) → margin expansion. Cross-model: revenue↑ (2025 +5.6%) + operating margin↑ (8.9%→~13.8%) → Quadrant 1 (ideal growth type). However, with organic volume near-flat, this is partly "restructuring-type growth" (margin up without organic volume). ROE ~9% — average by Gangbangcheon standards due to Evoqua dilution. Passes on FCF and margin improvement, but capital efficiency lags the 15%+ threshold.
Step 5
K-PER Valuation ❌ — Insufficient Safety Margin at Current Price
Normalized basis: 2025 adj. EPS ~$5.05, 3-year projection (→FY2028). Base (+23%) and optimistic (+56%) upsides are attractive, but conservative (-1%) falls short of the 10% threshold → Step 5 failed, Grade B. Analyst consensus target ~$150 (+37%) aligns between base and optimistic scenarios. At current $109, K-PER conservative target of $108 implies essentially flat return. Further decline below $100 would restore conservative upside to 10%+ → potential A upgrade.
K-PER Scenario Analysis (3-Year Target)
Base EPS: 2025 adj. EPS ~$5.05. Projection period: 3 years (FY2025→FY2028). Consensus EPS growth ~+10%/yr (analyst 3-year aggregate +43% ≈ CAGR 12.7%; conservatively applying 10% after incorporating 2026 guidance of +8%). K-PER multiples 17x (conservative) to 24x (optimistic) reflect subjective judgment — incorporating Xylem's historical PER, premium industrial peers, and PFAS/AI demand tailwinds. Conservative target price $108 implies -1% upside vs. current $109 — Step 5 failed.
| Scenario | Annual Growth | Non-GAAP Profit | Applied PER | Target Cap | Upside |
|---|---|---|---|---|---|
| Conservative (8% EPS Growth) | 연 8% EPS 성장 | FY2028 EPS $6.36 | 17x | ~$108 | -1% |
| Base (10% EPS Growth) | 연 10% EPS 성장 | FY2028 EPS $6.72 | 20x | ~$134 | +23% |
| Optimistic (12% EPS Growth) | 연 12% EPS 성장 | FY2028 EPS $7.09 | 24x | ~$170 | +56% |
Geochajesi Score (8/20)
Daily volume near average (~2.0M) — not 200%+ surge but meets large-cap baseline liquidity (+1). ~92.7% institutional ownership (passive/index-heavy) — structurally stable flow (+1). Active net-buying signal uncertain; UBS downgrade and sell recommendations co-existing. "Retail selling + institutional accumulation at lows" scenario possible but unconfirmed.
Full bearish alignment (200-day $130 > 50-day $115 > price $109) → immediate maximum 1-point cap (+1). Near 52-week low ($105.29) — potential for oversold bounce. Death cross (50-day crossing below 200-day) confirmed Feb–Mar 2026. RSI oversold (~30) in February and May → recovering to ~40. Trend reversal unconfirmed — no additional score for bullish alignment.
PFAS regulatory mandatory demand (+1): US EPA standards finalized → long-term recurring tailwind for MitiGATOR, activated carbon, membranes. AI water demand + aging infrastructure megatrend (+1): sector theme forming, 10-year+ structural demand. $1.5B buyback authorized Feb 2026 (+1): large shareholder return near lows provides medium-to-long-term downside support. Recent catalyst was negative (2026 conservative guidance, numerous target cuts); no imminent explosive catalyst.
Infrastructure/utility sector defensive characteristics — relative stability on market anxiety or recession fears (+1). Rising water infrastructure theme interest + policy momentum (IIJA, PFAS) (+1). But sustained underperformance vs. market near 52-week low. As of 2026-06-10, real-time S&P500/Nasdaq data unavailable — conservative scoring assuming neutral market conditions.
Entry Strategy (3 Tranches)
Enter 1/3 now near ~$109. Add 1/3 on $105 support defense confirmation. Final 1/3 after 50-day ($115–116) volume recapture. Target avg cost ~$107. Stop on clean break below $100. Target 1 ~$134 (K-PER base, R:R 2.3:1). Must use long-term conviction capital (1–3 years), not time-sensitive funds.
Further decline below $100 improves conservative K-PER upside to 8–15%+, establishing a safety margin (eligible for Gangbangcheon A upgrade). Stop: $88–90. Target 1 ~$134 (+37%), R:R 3.5:1. Requires patience for further decline vs. Scenario 1, but provides the strongest entry rationale.
50-day MA volume recapture → enter on pullback. Strongest entry rationale with trend reversal confirmed, but higher entry price reduces upside to Target 1 (~+16%). Stop: re-break below 50-day MA. Appropriate for conservative investors who prefer to eliminate bearish-alignment risk before entering.
Exit Triggers
Clean $100 close break → liquidate over half of position; re-evaluate after checking $90–$95 next support
K-PER base target ~$134 reached (+23%) → take profit on 1/3–1/2; hold remainder pending trend strength and 50-day MA stability
K-PER optimistic target ~$170 reached (+56%) → full exit on remaining shares; long-term holders reassess business model before deciding
Formal acknowledgment Evoqua revenue synergies cannot be realized, or ROE improvement reversal → business model impairment signal, immediate full position reassessment
Business model impairment — customer lock-in collapse, market share loss, PFAS regulatory reversal, Gangbangcheon Steps 1–4 downgrade → immediate full liquidation
Portfolio Weight Recommendation
New position deferred (lump-sum immediate entry not recommended). 3-tranche accumulation targeting 3–5% total weight. Long-term conviction investors may target 5–8% on further decline below $100. Time-sensitive capital absolutely prohibited.
Editor Note
"A-quality asset at a B-grade price." Xylem is a rare case in the Gangbangcheon framework — business quality is Grade A, but a single valuation gate (conservative K-PER -1%) brings it down to B. This doesn't mean the business is bad; it means the stock hasn't fallen enough yet. A further decline below $100 would restore conservative upside to 10%+ and potentially trigger an A upgrade. Paradoxically, for this stock to get cheap, things have to look worse first — PFAS implementation delays, additional guidance cuts, market fear. When that window arrives, it becomes a rare entry opportunity for long-term investors. Set a $100 price alert on your watchlist.
Financial Data
Fiscal year: calendar year (Jan–Dec). FY2025 = January–December 2025 (completed and reported). Currently in FY2026 Q2 (April–June 2026). K-PER projection period: 3 years out = FY2028 (ending December 2028). Financial figures in USD billions ($B). Operating income (2021, 2022, 2025) and ROE/ROA (all years except 2023) are estimates — to be updated with confirmed FY2025 10-K figures.
| Period | Revenue | Growth | Op. Income | Op. Margin |
|---|---|---|---|---|
| FY2023Evoqua $7.5B all-stock acquisition completed May 2023. Revenue jumped from $5.5B to $7.4B. Integration one-time costs and restructuring diluted margin to 8.9%. ROE 6.0% (confirmed), ROA 3.8% (confirmed) — structural dilution from capital/asset roughly doubling on acquisition. | $7.36B | +33.3% YoY (Evoqua 인수 효과) | $652M | 8.9% |
| FY2024Record revenue achieved. 80/20 simplification, non-core disposal, and Evoqua integration stabilization drove margin improvement from 8.9% to 11.8%. ROE ~8.6% (est.) and ROA ~5.5% (est.) recovering from Evoqua dilution. Adj. EPS $4.23 (+19% YoY). Backlog $5B (record $8.7B new orders). | $8.56B | +16.3% YoY | $1,009M | 11.8% |
| FY2025Consecutive record revenue. Margin improving to ~13.8% (est.). Adj. EPS ~$5.05 (+19% YoY). Adj. EBITDA margin 22.2% (+160bp). ROE ~9.0% (est.), ROA ~6.0% (est.). $4.6B backlog. Organic volume near-flat (purposeful walkaway + China de-risking) + price realization driving margin-first strategy. | $9.04B | +5.6% YoY | ~$1,250M | ~13.8% (추정) |
GAAP vs Non-GAAP Note
Xylem applies US GAAP and files 10-K (annual) and 10-Q (quarterly) with the SEC as a NYSE-listed US corporation. Reported GAAP earnings differ significantly from adjusted (Non-GAAP) earnings due to stock-based compensation, acquisition-related intangible amortization, and restructuring costs. Goodwill and intangible assets from the Evoqua acquisition are substantial — implying future impairment test risk. Segment revenue mix breakdown requires confirmation against the FY2025 10-K confirmed figures (current data is approximate). FY2025 operating income ($1,250M), ROE, and ROA are estimates derived from disclosed EPS, interest expense, and balance sheet — may differ from 10-K confirmed figures. FCF margin estimate of 10–12% requires cash flow statement verification.
Key Valuation Metrics
K-PER Base Target (FY2028)
~$134 (+23%)
Base EPS growth 10%/yr → FY2028 EPS $6.72 × K-PER 20x = ~$134. Analyst consensus target ~$150 (+37%) sits between base and optimistic scenarios. Safety margin zone from current $109.
K-PER Conservative Target (FY2028)
~$108 (-1%)
Conservative EPS growth 8%/yr → FY2028 EPS $6.36 × K-PER 17x = ~$108. -1% upside from current price — below the 10% safety-margin threshold, the core basis for Gangbangcheon B rating. Below $100 further decline would improve conservative upside to 8–15%+.
Adj. EPS / EBITDA Margin (2025)
~$5.05 / 22.2%
Adj. EPS +19% YoY ($4.23 in 2024 → ~$5.05 in 2025). Adj. EBITDA margin 22.2% (+160bp YoY). 2026 guidance: adj. EPS $5.24–$5.48, adj. EBITDA margin ~23%. Margin improvement trend continues but pace fell short of consensus expectations, contributing to the stock decline.
ROE / ROA (2025 est.)
~9% / ~6%
ROE diluted to 6.0% (2023) by Evoqua acquisition, recovering to ~9% (2024 ~8.6% → 2025 ~9%). 6 percentage points below Gangbangcheon "superior compounder (15%+)" standard. If margin improvement continues, 11–13% is achievable by 2027–2028 (estimate). ROA recovering from 3.8% (2023 low) to ~6.0% (2025 est.).
Backlog / Evoqua Synergies
$4.6B / $130M 런레이트
Backlog $4.6B (~60% to be recognized in 2026) — high revenue visibility. Evoqua cost synergy run-rate $130M (vs. $140M target, ahead of 3-year plan). Revenue synergies currently in progress and unrealized — explicitly noted as a key uncertainty in SEC filings. 2025 backlog is quantitative evidence of demand defensiveness.
$1.5B Buyback / Dividend
$1.5B 승인 + 15년 연속 증가
$1.5B share buyback program authorized February 2026. Large-scale repurchase near 52-week lows provides downside price support. 15 consecutive years of dividend increases establishes long-term shareholder return credibility. Total 2024 shareholder returns ~$350M. Capital allocation priority: growth investment > dividends > buybacks.
* GAAP basis. All figures are estimates based on public information and are not investment advice.
Same Exchange
- DEJohn Deere (DE): Gangbangcheon B × Geochajesi 9/20 — North America Ag Machinery #1, Triple Moat, FY2026 Cycle Trough, Watch-and-Wait as Price Exceeds K-PER Base ($469)
- BABAAlibaba (BABA): Gangbangcheon B × Geochajesi 6/20 — China Cloud/AI #1 + Proprietary Chip Vertical Integration, FY2026 Margin Collapse Watch-and-Wait
- HLFHerbalife (HLF): Gangbangcheon C × Geochajesi 11/20 — Extreme EV/EBITDA 4.8x Undervaluation, Refinancing Game-Changer Amid GLP-1 Threat, Watch-and-Wait